Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of RDX5791 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

NCT01340053 is registered in ClinicalTrials.gov with Ardelyx as lead sponsor.

NCT NCT01340053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01340053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of RDX5791 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Lead sponsor
Ardelyx
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2011
Completion date
February 29, 2012
Enrollment
186 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

constipation predominant irritable bowel syndrome